RhumbLine Advisers’s Climb Bio CLYM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$562K Buy
48,979
+4,435
+10% +$61.8K ﹤0.01% 2653
2026
Q2
$581K Buy
+44,544
New +$460K ﹤0.01% 2672
2025
Q2
– Sell
-24,782
Closed -$30.2K – 4294
2025
Q1
$30.2K Sell
24,782
-7,054
-22% -$11.4K ﹤0.01% 3671
2024
Q4
$57.3K Buy
31,836
+4,096
+15% +$14.8K ﹤0.01% 3622
2024
Q3
$141K Buy
27,740
+19,507
+237% +$138K ﹤0.01% 3392
2024
Q2
$58.5K Buy
+8,233
New +$54.8K ﹤0.01% 3646

Other funds holding CLYM

RhumbLine Advisers's CLYM Position: Q3 2026 in Review

RhumbLine Advisers increased its Climb Bio (CLYM) stake by 10% in Q3 2026, buying an estimated $61.8K and bringing the position to 48,979 shares worth $562K. The position accounts for ﹤0.01% of the portfolio, ranked #2653.

RhumbLine Advisers first reported a position in CLYM in Q2 2024 and has held it in 6 quarters since. The position peaked at $581K in Q2 2026. 128 funds tracked by Wall St. Rank hold CLYM as of Q3 2026.

  • RhumbLine Advisers held 48,979 shares of Climb Bio worth $562K as of Q3 2026.
  • RhumbLine Advisers bought 4,435 Climb Bio shares in Q3 2026, an estimated $61.8K.
  • Climb Bio made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2653 holding.
  • RhumbLine Advisers first reported a position in Climb Bio in Q2 2024 and has held it in 6 quarters since.
  • RhumbLine Advisers's Climb Bio position peaked at $581K in Q2 2026.
  • 128 funds tracked by Wall St. Rank held Climb Bio as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.